Patents Represented by Attorney, Agent or Law Firm Thomas Hoxie
  • Patent number: 6451558
    Abstract: The present invention provides three novel HSC genes designated SCM 3, SCM 26, and SCM 113, the coding regions thereof, the gene products, applications of the genes, DNA constructs, vectors and transformed cells each comprising the gene of a fragment thereof. Methods of using the SCM 3, SCM 26 and SCM 113 polynucleotide and polypeptide sequences are also disclosed.
    Type: Grant
    Filed: July 27, 1999
    Date of Patent: September 17, 2002
    Assignee: Novartis AG
    Inventors: Michael Paul Cooke, Claire Louise Holness, Oksana Ivanivna Sirenko
  • Patent number: 6242003
    Abstract: An oral dosage form comprising fluvastatin and HPMC, which oral dosage form is color-stable upon prolonged periods of storage.
    Type: Grant
    Filed: April 13, 2000
    Date of Patent: June 5, 2001
    Assignee: Novartis AG
    Inventors: Oskar Michael Kalb, Stephen John Valazza
  • Patent number: 6225345
    Abstract: The invention relates to compounds of formula (I): wherein R1 and R10 are each independently of the other lower alkoxycarbonyl; either R2, R3 and R4 are each independently of the other C1-C4alkyl and R7, R8 and R9 are each selected from hydrogen and C1-C4alkyl, with not more than 2 of the radicals being hydrogen; or R7, R8 and R9 are each independently of the other C1-C4alkyl and R2, R3 and R4 are each selected from hydrogen and C1-C4alkyl, with 1 or 2 of the radicals being hydrogen; R5 is phenyl or cyclohexyl; and R6 is phenyl or cyanophenyl; or salts thereof; those compounds are inhibitors of retroviral aspartate proteases and are effective, for example, against HIV.
    Type: Grant
    Filed: May 21, 1998
    Date of Patent: May 1, 2001
    Assignee: Novartis AG
    Inventors: Alexander Fässler, Guido Bold, Hans-Georg Capraro, Marc Lang
  • Patent number: 6218508
    Abstract: An anti-microbial protein comprising a peptide having the amino acid sequence: AA1-AA2-AA3-Cys-AA5-AA6-AA7-AA8-AA9-CYS-AA11-AA12-AA13-AA14-Cys-Cys-AA17-AA18-AA19-AA20-AA21-Cys-AA23-AA24-AA25-AA26-AA27-AA28-Cys-AA30. An anti-microbial protein having the sequence depicted in any one of SEQ ID Nos 1-3. Recombinant DNA encoding such proteins. A vector comprising such DNA which is expressible in plants and which is linked to a plant operable promoter and terminator. Plants transformed with such recombinant DNA; the progeny of such plants which contain the DNA stably incorporated and hereditable in a Mendelian manner, and/or the seeds of such plants or such progeny.
    Type: Grant
    Filed: April 17, 1996
    Date of Patent: April 17, 2001
    Assignee: Novartis AG
    Inventors: Karsten Matthias Kragh, Jørn Dalgaard Mikkelsen, Klaus Kristian Nielsen
  • Patent number: 6162802
    Abstract: A method for the treatment of a variety of cardiovascular disorders and related conditions in a mammal having at least one such disorder or condition is disclosed comprising treating the mammal with cotherapy comprising benazepril and amlodipine or pharmaceutically acceptable salts of either or both. Combination formulations of benazepril and amlodipine for use in the method are also disclosed.
    Type: Grant
    Filed: March 10, 1992
    Date of Patent: December 19, 2000
    Inventors: Joseph Papa, Marc M. J. Henis
  • Patent number: 6162965
    Abstract: An improved method of Agrobacterium transformation of plants, particularly Gramineae, is provided, utilizing conditions capable of inhibiting Agrobacterium-induced necrosis.
    Type: Grant
    Filed: June 2, 1998
    Date of Patent: December 19, 2000
    Assignee: Novartis AG
    Inventor: Genevieve Hansen
  • Patent number: 6150585
    Abstract: Recombinant DNA constructs comprising a DNA coding for transcription into an RNA sequence of tospoviruses or into RNA sequences related thereto, the use of such DNA constructs to transform plants having reduced susceptibility to tospovirus infection and probes for the isolation of tospovirus or diagnosis of plant tospovirus diseases.
    Type: Grant
    Filed: November 26, 1996
    Date of Patent: November 21, 2000
    Assignee: Novartis Finance Corporation
    Inventors: Robert Willem Goldbach, Dirk Peters, Johannes Jacobus Ludgerus Gielen, Petrus Theodorus de Haan, Arnoldus Johannes Kool, Martinus Quirinus Joseph Marie van Grinsven
  • Patent number: 6114608
    Abstract: The present invention is drawn to a novel DNA construct comprising an expression cassette having a constitutive promoter which functions in plant cells operably linked to a maize alcohol dehydrogenase intron, a DNA sequence of a gene encoding a Cry 1Ab protein, and a terminator functional in plants and optionally further comprising a second cassette including a promoter which functions in plants operably linked to a maize alcohol dehydrogenase intron, a DNA sequence of a gene encoding for phosphinothricin acetyl transferase, and a terminator functional in plants wherein the two cassettes are transcribed in the same direction. Also provided are transgenic plants, particularly maize plants, having such a construct stably incorporated into their genomes.
    Type: Grant
    Filed: March 13, 1998
    Date of Patent: September 5, 2000
    Assignee: Novartis AG
    Inventors: Irvin J Mettler, Paul S Dietrich, Ralph M. Sinibaldi
  • Patent number: 6084158
    Abstract: The invention is a novel soybean cultivar designated M003360 with high yield potential and tolerance to glyphosate herbicide. The invention relates to seeds of the cultivar M003360, plants of the cultivar M003360, and to methods for producing a soybean plant produced by crossing the soybean M003360 by itself or another soybean genotype.
    Type: Grant
    Filed: February 12, 1999
    Date of Patent: July 4, 2000
    Assignee: Novartis AG
    Inventor: Kevin Threlkeld
  • Patent number: 6072110
    Abstract: An inbred maize line, designated NP2029, the plants and seeds of inbred maize line NP2029, methods for producing a maize plant produced by crossing the inbred line NP2029 with itself or with another maize plant, and hybrid maize seeds and plants produced by crossing the inbred line NP2029 with another maize line or plant.
    Type: Grant
    Filed: January 19, 1999
    Date of Patent: June 6, 2000
    Assignee: Novartis AG
    Inventor: Allen Henson
  • Patent number: 6066784
    Abstract: The invention is a novel soybean cultivar designated J335752 with high yield potential, early Group 4 maturity, and resistance to races 3 and 14 of Soybean Cyst Nematode. The invention relates to seeds of the cultivar J335752, plants of the cultivar J335752, and to methods for producing a soybean plant by crossing of the cultivar J335752 by itself or another soybean genotype.
    Type: Grant
    Filed: February 12, 1999
    Date of Patent: May 23, 2000
    Assignee: Novartis AG
    Inventor: Roger McBroom
  • Patent number: 6057492
    Abstract: Plant transformation vectors comprising a polynucleotide effective to render resisitance or tolerance to infection by a tospovirus, and a microbiological process for making virus tolerant or resistant plants are provided herein.
    Type: Grant
    Filed: September 18, 1997
    Date of Patent: May 2, 2000
    Assignee: Novartis AB
    Inventor: Petrus Theodorus de Haan
  • Patent number: 6051409
    Abstract: The present invention provides an improved method for achieving stable integration of an exogenous DNA fragment in intact form into the genome of a eukaryotic cell, particularly a plant cell. The method comprises providing the exogenous DNA together with one or more proteins which promote integration of the exogenous DNA to the eukaryotic cell targeted for transformation, wherein the proteins are provided in the form of a chimeric gene or translatable RNA capable of expression in the eukaryotic cell. The method is particularly applied to plant cells to achieve stable integration of an exogenous DNA fragment bounded by T-DNA borders in intact form using integration-promoting proteins derived from Agrobacterium. Transgenic cultures, tissues and whole organisms, particularly transgenic plants, can be generated from cells transformed according to the method of the invention.
    Type: Grant
    Filed: September 23, 1996
    Date of Patent: April 18, 2000
    Assignee: Novartis Finance Corporation
    Inventors: Genevieve Hansen, Mary-Dell Chilton
  • Patent number: 6040504
    Abstract: A promoter isolated from a cotton gene encoding the small subunit of ribulose bisphosphate carboxylase is described. The isolated promoter is operably linked to a coding sequence of interest to make a chimeric gene.
    Type: Grant
    Filed: February 10, 1998
    Date of Patent: March 21, 2000
    Assignee: Novartis Finance Corporation
    Inventors: Douglas Rice, Nadine Carozzi, David M. Anderson, Kanniah Rajasekaran, Thirumale S. Rangan, Richard Yenofsky, Richard Lotstein
  • Patent number: 6040502
    Abstract: The invention is a novel soybean cultivar designated C405323 with high yield potential, early Group 2 maturity, seed with yellow hila for food grade markets and resistance to Races 1-3, 6-9 of Phytopthora sojae. The invention relates to seeds of the cultivar C405323, plants of the cultivar C405323 and to methods for producing a soybean plant by crossing of the cultivar C405323 by itself or with another soybean genotype.
    Type: Grant
    Filed: February 15, 1999
    Date of Patent: March 21, 2000
    Assignee: Novartis AG
    Inventors: Kevin Threlkeld, Donald McClure
  • Patent number: 6040496
    Abstract: The present invention provides methods and compositions for inhibiting virus infection in susceptible monocotyledonous plants. The methods and compositions involve the production of translationally altered forms of messenger RNA sequence derived from the inhibited virus. The invention further provides structural and organizational information for the genome of strain B of maize dwarf mosaic virus. Methods for inhibiting MDMV-B infection are taught. These methods include the generation of transformed plants containing chimeric genes capable of expressing either MDMV-B proteins or translationally altered forms of messenger RNA sequences produced by MDMV-B.
    Type: Grant
    Filed: June 30, 1995
    Date of Patent: March 21, 2000
    Assignee: Novartis Finance Corporation
    Inventors: Marcus Dixon Law, Jon M. Dietz
  • Patent number: 6040501
    Abstract: The invention is a novel soybean cultivar designated B630518RR with high yield potential and tolerance to glyphosate herbicide. The invention relates to seeds of the cultivar B630518RR, plants of the cultivar B630518RR, and to methods for producing a soybean plant produced by crossing the soybean B630518RR by itself or another soybean genotype.
    Type: Grant
    Filed: February 12, 1999
    Date of Patent: March 21, 2000
    Assignee: Novartis AG
    Inventor: Howard L. Gabe
  • Patent number: 6037528
    Abstract: The invention is a novel soybean cultivar designated C910928 with high yield potential, late Group 1 maturity, excellent lodging scores, and tolerance or resistance to several important diseases. The invention relates to the seeds of C910928 and to methods for producing a soybean plant by crossing of the cultivar by itself or with another soybean genotype.
    Type: Grant
    Filed: February 15, 1999
    Date of Patent: March 14, 2000
    Assignee: Novartis AG
    Inventor: Donald McClure
  • Patent number: PP11197
    Abstract: A new and distinct variety of Verbena plant, named Silvena, characterized particularly as to novelty by large, early-appearing purple flowers, and a growth habit that is initially semi-erect but later spreading and hanging.
    Type: Grant
    Filed: March 27, 1997
    Date of Patent: February 1, 2000
    Assignee: Novartis AG
    Inventor: Henricus G. W. Stemkens
  • Patent number: PP11231
    Abstract: A new and distinct variety of Verbena plant, named Morena, characterized particularly as to novelty by large, early-appearing, vivid pink flowers, and a growth habit that is initially semi-erect but later spreading and hanging.
    Type: Grant
    Filed: March 27, 1997
    Date of Patent: February 22, 2000
    Assignee: Novartis AG
    Inventor: Henricus G. W. Stemkens